Patients under anti-platelet therapy

Best Practice and Research: Clinical Anaesthesiology

Volumn 24, Issue 1, 2010, Pages 41-50

  Albaladejo, Pierre ^a   Samama, Charles Marc ^b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b HÔTEL DIEU   (France)

Author keywords

anti platelet agents; aspirin; bleeding; clopidogrel; prasugrel; stent; surgery; thrombosis

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE;

ANTICOAGULANT THERAPY; ATHEROTHROMBOSIS; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG INDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEMATURIA; HEMOSPERMIA; HUMAN; INVASIVE PROCEDURE; LOADING DRUG DOSE; LOW DRUG DOSE; PERIPHERAL VASCULAR DISEASE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECTUM HEMORRHAGE; REVIEW; STENT; STENT THROMBOSIS; SURGICAL TECHNIQUE; THROMBOSIS;

ANIMALS; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 77349122335     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2009.09.008     Document Type: Review

References (48)

1. Nuttall G.A., Brown M.J., Stombaugh J.W., et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology 109 (2008) 588-595
2. Rabbitts J.A., Nuttall G.A., Brown M.J., et al. Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents. Anesthesiology 109 (2008) 596-604
3. Chassot P.G., Delabays A., and Spahn D.R. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. British Journal of Anaesthesia 99 (2007) 316-328
4. Douketis J.D., Berger P.B., Dunn A.S., et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008) 299S-339S
5. Albaladejo P., Marret E., Piriou V., et al. Perioperative management of antiplatelet agents in patients with coronary stents: recommendations of a French Task Force. British journal of anaesthesia 97 (2006) 580-582
6. Fleisher L.A., Beckman J.A., Brown K.A., et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 116 (2007) 1971-1996
7. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
8. Patrono C., Baigent C., Hirsh J., et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 133 (2008) 199S-233S
9. Patrono C., Coller B., FitzGerald G.A., et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 234S-264S
10. Pena A., Collet J.P., Hulot J.S., et al. Can we override clopidogrel resistance?. Circulation 119 (2009) 2854-2857
11. Angiolillo D.J., Bhatt D.L., Gurbel P.A., et al. Advances in antiplatelet therapy: agents in clinical development. The American journal of cardiology 103 (2009) 40A-51A
12. Baigent C., Blackwell L., Collins R., et al., Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009) 1849-1860
13. CAPRIE steering committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
14. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England Journal of Medicine 354 (2006) 1706-1717
15. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine 357 (2007) 2001-2015
16. FitzGerald G.A., Oates J.A., Hawiger J., et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. The Journal of Clinical Investigation 71 (1983) 676-688
17. Cahill R.A., McGreal G.T., Crowe B.H., et al. Duration of increased bleeding tendency after cessation of aspirin therapy. Journal of the American College of Surgeons 200 (2005) 564-573
18. Price M.J., and Teirstein P.S. Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers. The American Journal of Cardiology 102 (2008) 790-795
19. Berger J.S., Frye C.B., Harshaw Q., et al. Impact of Clopidogrel in Patients With Acute Coronary Syndromes Requiring Coronary Artery Bypass. Journal of The American College of Cardiology 52 (2008) 1693-1701
20. Fatah K., Beving H., Albage A., et al. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient?. European Heart Journal 17 (1996) 1362-1366
21. Beving H., Zhao C., Albage A., et al. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagulation & Fibrinolysis 7 (1996) 80-84
22. Vial J.H., McLeod L.J., and Roberts M.S. Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal. Advances in Prostaglandin, Thromboxane, and Leukotriene Research 21A (1991) 157-160
23. Louwerenburg J.W., Suttorp M.J., and Herie Kingma J. Aspirin withdrawal in a patient with essential thrombocythemia: possible cause of myocardial infarction. The American Journal of Medicine 83 (1987) 1175
24. Krnic-Barrie S., O'Connor C.R., Looney S.W., et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Archives of Internal Medicine 157 (1997) 2101-2108
25. Collet J.P., Montalescot G., Blanchet B., et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 110 (2004) 2361-2367
26. Ferrari E., Benhamou M., Cerboni P., et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. Journal of the American College of Cardiology 45 (2005) 456-459
27. Bachman D.S. Discontinuing chronic aspirin therapy: another risk factor for stroke?. Annals of Neurology 51 (2002) 137-138
28. Maulaz A.B., Bezerra D.C., Michel P., et al. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Archives of Neurology 62 (2005) 1217-1220
29. Sibon I., and Orgogozo J.M. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 62 (2004) 1187-1189
30. Albaladejo P., Geeraerts T., Francis F., et al. Aspirin withdrawal and acute lower limb ischemia. Anesthesia and Analgesia 99 (2004) 440-443 table of contents
31. Kaluza G.L., Joseph J., Lee J.R., et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. Journal of the American College of Cardiology 35 (2000) 1288-1294
32. Vicenzi M.N., Meislitzer T., Heitzinger B., et al. Coronary artery stenting and non-cardiac surgery-a prospective outcome study. British Journal of Anaesthesia 96 (2006) 686-693
33. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
34. Ong A.T., McFadden E.P., Regar E., et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. Journal of the American College of Cardiology 45 (2005) 2088-2092
35. Eisenberg M.J., Richard P.R., Libersan D., et al. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 119 (2009) 1634-1642
36. Godet G., Le Manach Y., Lesache F., et al. Drug-eluting stent thrombosis in patients undergoing non-cardiac surgery: is it always a problem?. British Journal of Anaesthesia 100 (2008) 472-477
37. Schouten O., van Domburg R.T., Bax J.J., et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy. Journal of the American College of Cardiology (2007)
38. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355 (2000) 1295-1302
39. Burger W., Chemnitius J.M., Kneissl G.D., et al. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. Journal of Internal Medicine 257 (2005) 399-414
40. Giannarini G., Mogorovich A., Valent F., et al. Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urology 70 (2007) 501-505
41. Ehrlich Y., Yossepowitch O., Margel D., et al. Early initiation of aspirin after prostate and transurethral bladder surgeries is not associated with increased incidence of postoperative bleeding: a prospective, randomized trial. The Journal of Urology 178 (2007) 524-528 discussion 528
42. Samama C.M., Bastien O., Forestier F., et al. Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR). Canadian Journal of Anaesthesia (Journal canadien d'anesthésie) 2002 49 (2001) S26-S35
43. O'Riordan J.M., Margey R.J., Blake G., et al. Antiplatelet agents in the perioperative period. Archives of Surgery (Chicago, Ill:1960) 144 (2009) 69-76 discussion 76
44. Sobel M., Verhaeghe R., Physicians ACoC, et al. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 133 (2008) 815S-843S
45. Ebrahimi R., Dyke C., Mehran R., et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. Journal of the American College of Cardiology 53 (2009) 1965-1972
46. Samama C.M., Bonnin P., Bonneau M., et al. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thrombosis and Haemostasis 68 (1992) 500-505
47. Samama C.M., Thiry D., Elalamy I., et al. Perioperative activation of hemostasis in vascular surgery patients. Anesthesiology 94 (2001) 74-78
48. Rosencher N., Vielpeau C., Emmerich J., et al. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. Journal of Thrombosis and Haemostasis 3 (2005) 2006-2014